These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 32534346)

  • 41. Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis.
    Mo H; Zhang R; Chen Y; Li S; Wang Y; Zou W; Lin Q; Zhao DG; Du Y; Zhang K; Ma YY
    Eur J Med Chem; 2022 Dec; 243():114705. PubMed ID: 36215854
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
    Ding C; Chen S; Zhang C; Hu G; Zhang W; Li L; Chen YZ; Tan C; Jiang Y
    Bioorg Med Chem; 2017 Jan; 25(1):27-37. PubMed ID: 27769671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
    Zhao N; Yang F; Han L; Qu Y; Ge D; Zhang H
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32046013
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms.
    Mehndiratta S; Chen MC; Chao YH; Lee CH; Liou JP; Lai MJ; Lee HY
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):74-84. PubMed ID: 33161799
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
    Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
    Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
    Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H
    Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity.
    Ibrahim TS; Sheha TA; Abo-Dya NE; AlAwadh MA; Alhakamy NA; Abdel-Samii ZK; Panda SS; Abuo-Rahma GEA; Mohamed MFA
    Bioorg Chem; 2020 Jun; 99():103797. PubMed ID: 32247939
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
    Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
    Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors.
    Wang L; Hou X; Fu H; Pan X; Xu W; Tang W; Fang H
    Bioorg Med Chem; 2015 Aug; 23(15):4364-4374. PubMed ID: 26149591
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
    Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
    Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
    Mustafa M; Abd El-Hafeez AA; Abdelhamid D; Katkar GD; Mostafa YA; Ghosh P; Hayallah AM; Abuo-Rahma GEA
    Eur J Med Chem; 2021 Oct; 222():113569. PubMed ID: 34111829
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular design, synthesis and
    Abdel-Atty MM; Farag NA; Serya RAT; Abouzid KAM; Mowafy S
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1290-1312. PubMed ID: 34187263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
    Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W
    J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
    Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
    J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
    Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
    Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors.
    Ning C; Bi Y; He Y; Huang W; Liu L; Li Y; Zhang S; Liu X; Yu N
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6432-5. PubMed ID: 24119555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
    Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
    Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.